Michael Mourez worked at Sanofi as Head of the antibacterial discovery portfolio in the therapeutic area of infectious diseases and then at Evotec where he oversaw technology platforms addressing severe bacterial infections, especially drug resistance.
Prior to his work in industry, Michael held positions as an assistant and then tenured professor at the University of Montreal in Canada. Here, he developed a research programme on virulence factors of pathogenic Escherichia coli at the school of veterinary medicine, and he held a Canada Research Chair on bacterial animal diseases as well as numerous grants and awards. He is an author of over 50 peer-reviewed journal articles and an inventor of several patents.
Michael trained in the fields of Gram-negative bacteria envelope physiology and bacterial pathogenesis. After graduating from École Polytechnique with an engineering degree, Michael obtained a PhD in fundamental bacteriology at the Institut Pasteur in Paris, working on ATP Binding Cassette transporters, followed by a post-doctoral fellowship at Harvard Medical School in Boston, working on anthrax toxins.